Document:

EX-4.2

 Exhibit 4.2 

Execution Version 
 AMENDED AND
RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	 Definitions
	  	 	1	 
			
	 2.
	 	 Registration Rights
	  	 	6	 
				
		 	 2.1
	  	 Demand Registration
	  	 	6	 
		 	 2.2
	  	 Company Registration
	  	 	8	 
		 	 2.3
	  	 Underwriting Requirements
	  	 	8	 
		 	 2.4
	  	 Obligations of the Company
	  	 	10	 
		 	 2.5
	  	 Furnish Information
	  	 	11	 
		 	 2.6
	  	 Expenses of Registration
	  	 	11	 
		 	 2.7
	  	 Delay of Registration
	  	 	12	 
		 	 2.8
	  	 Indemnification
	  	 	12	 
		 	 2.9
	  	 Reports Under Exchange Act
	  	 	14	 
		 	 2.10
	  	 Limitations on Subsequent Registration Rights
	  	 	15	 
		 	 2.11
	  	 Market Stand-off Agreement
	  	 	15	 
		 	 2.12
	  	 Restrictions on Transfer
	  	 	16	 
		 	 2.13
	  	 Termination of Registration Rights
	  	 	17	 
			
	 3.
	 	 Financial Information and Reporting
	  	 	17	 
				
		 	 3.1
	  	 Delivery of Consolidated Financial Statements
	  	 	17	 
		 	 3.2
	  	 Inspection
	  	 	19	 
		 	 3.3
	  	 Termination of Information Rights
	  	 	19	 
		 	 3.4
	  	 Confidentiality
	  	 	19	 
			
	 4.
	 	 Rights to Future Stock Issuances
	  	 	20	 
				
		 	 4.1
	  	 Right of First Offer
	  	 	20	 
		 	 4.2
	  	 Termination
	  	 	23	 
			
	 5.
	 	 Additional Covenants
	  	 	23	 
				
		 	 5.1
	  	 Insurance
	  	 	23	 
		 	 5.2
	  	 Employee Agreements
	  	 	24	 
		 	 5.3
	  	 Employee Stock
	  	 	24	 
		 	 5.4
	  	 Qualified Small Business Stock
	  	 	24	 
		 	 5.5
	  	 Board Matters
	  	 	25	 
		 	 5.6
	  	 Successor Indemnification
	  	 	25	 
		 	 5.7
	  	 Expenses of Counsel
	  	 	25	 
		 	 5.8
	  	 Indemnification Matters
	  	 	26	 
		 	 5.9
	  	 Termination of Covenants
	  	 	26	 
		 	 5.10
	  	 Right to Conduct Activities
	  	 	26	 

  
 - i - 

									
	 6.
	 	 Miscellaneous
	  	 	27	 
				
		 	 6.1
	  	 Successors and Assigns
	  	 	27	 
		 	 6.2
	  	 Governing Law
	  	 	28	 
		 	 6.3
	  	 Counterparts
	  	 	28	 
		 	 6.4
	  	 Titles and Subtitles
	  	 	28	 
		 	 6.5
	  	 Notices
	  	 	28	 
		 	 6.6
	  	 Amendments and Waivers
	  	 	28	 
		 	 6.7
	  	 Severability
	  	 	29	 
		 	 6.8
	  	 Aggregation of Stock
	  	 	29	 
		 	 6.9
	  	 Additional Investors
	  	 	29	 
		 	 6.10
	  	 Entire Agreement
	  	 	29	 
		 	 6.11
	  	 Dispute Resolution
	  	 	30	 
		 	 6.12
	  	 Delays or Omissions
	  	 	30	 
		 	 6.13
	  	 Acknowledgment
	  	 	31	 
		 	 6.14
	  	 Effectiveness
	  	 	31	 

  

					
	Schedule A	  	-	  	Schedule of Investors
			
	Schedule B	  	-	  	Schedule of Key Holders
			
	Exhibit A	  	-	  	Form of Noncompetition and Nonsolicitation Agreement

  
 - ii - 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 7th day of August, 2017, by and among Apellis Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed
on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess information rights, preemptive rights, and other rights pursuant to that certain
Investors’ Rights Agreement, dated December 24, 2015, among the Company and such Investors (the “Prior Agreement”); and 

WHEREAS, the Existing Investors are holders of at least a majority of the outstanding Registrable Securities (as defined in the Prior
Agreement), and desire to amend and restate the Prior Agreement in its entirety and to supersede the Prior Agreement by this Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series E Preferred Stock Purchase Agreement of even date herewith between
the Company and certain of the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement; 

NOW, THEREFORE, in consideration of mutual covenants set forth herein, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree that the Prior Agreement shall be amended, restated, superseded and replaced in its entirety by this Agreement, and the parties to this Agreement further agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, limited partner, member, manager, managing member, officer or director of such Person or any venture capital fund now or hereafter existing
that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. “Affiliate” shall also mean, with respect to F-Prime Capital
Partners Healthcare Fund V LP (“F-Prime”), for so long as F-Prime holds any shares of the Company, no more than ten (10) employees of FMR LLC to
whom F-Prime or its Affiliate (as defined in the preceding sentence) has transferred shares of the Company (it being understood that only an ownership interest in such shares shall be transferred, not an
assignment of any contractual 

 
rights that F-Prime may have in connection with F-Prime’s ownership of shares of the Company). For purposes of
this definition, the term “control” when used with respect to any Person shall mean the power to direct the management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract
or otherwise, and the terms “controlling” and “controlled” shall have meanings correlative to the foregoing. 

1.2 “Certificate of Incorporation” means the Seventh Amended and Restated Certificate of Incorporation of the Company, as
amended from time to time. 
 1.3 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per
share. 
 1.4 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited
liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in development of complement inhibitors for indicators presently considered by the Company, but shall not include any financial
investment firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the Board of
Directors of any Competitor. 
 1.5 “Damages” means any loss, damage, claim or liability (joint or several) to which a party
hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or
alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of
the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.6 “Deemed Liquidation Event” has the meaning assigned to such term in the Certificate of Incorporation. 

1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case,
directly or indirectly), Common Stock, including options and warrants. 
 1.8 “Exchange Act” means the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

  
 - 2 - 

 1.9 “Excluded Registration” means (i) a registration relating to the sale
of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. 
 1.10 “Excluded Securities” means (i) Common Stock
issued as a stock dividend to holders of Common Stock or upon any subdivision of shares of Common Stock; (ii) Preferred Stock issued as a stock dividend to holders of Preferred Stock or upon any subdivision of shares of Preferred Stock;
(iii) the issuance of shares of Common Stock, or options exercisable therefor, including options outstanding on the date of this Agreement, issued or issuable to current or former employees, officers or directors of, or consultants or advisers
to, the Company pursuant to stock purchase or stock option plans or similar arrangements approved by the Board of Directors; (iv) securities issued or issuable in connection with a bona fide non-equity
financing transaction (e.g. equipment financing arrangements and bank lines of credit) that is approved by the Board of Directors; (v) securities issued solely in consideration for the acquisition (whether by merger or otherwise) by the
Company or any of its subsidiaries of all or substantially all of the stock or assets of any other entity in a transaction that is approved by the Board of Directors; (vi) shares of Common Stock issued in a Qualified IPO; (vii) securities
issued to a strategic partner in connection with a development, collaboration or other similar agreement that is approved by the Board of Directors; (viii) securities issued, sold or exchanged by the Company as to which the holders of at least
a majority of the combined voting power of the shares of the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock, voting together, have elected to designate as Excluded Securities and
such issuance, sale or exchange of securities has been approved by the Board (including the affirmative approval of at least one (1) Series E Director); or (ix) shares of Series E Preferred Stock issued pursuant to the Purchase Agreement.

 1.11 “FOIA Party” means a Person that, in the reasonable determination of the Board of Directors, may be subject to, and
thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access
law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.12 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.13 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 

  
 - 3 - 

 1.14 “GAAP” means generally accepted accounting principles in the United States.

 1.15 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.16 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.17 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.18 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.19 “Key Employee” means any executive-level employee (including division director and vice president-level
positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.20 “Major Investor” means any holder of at least 5.0% of the Registrable Securities then outstanding. 

1.21 “New Securities” means, collectively, equity securities of the Company (or any debt securities that may be
convertible into equity securities of the Company), whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or
exchangeable into or exercisable for such equity securities. 
 1.22 “Person” means any individual, corporation,
partnership, trust, limited liability company, association or other entity. 
 1.23 “Preferred Directors” means the Series C
Directors, the Series D Directors and any Series E Directors. 
 1.24 “Preferred Stock” means, collectively, shares
of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 

1.25 “Qualified IPO” has the meaning assigned to the term “Qualified Public Offering” in the Certificate of
Incorporation. 

  
 - 4 - 

 1.26 “Registrable Securities” means (i) the Common Stock issuable or issued
upon conversion of the Preferred Stock, excluding any Common Stock issued upon conversion of the Series E Preferred Stock pursuant to Section 5.3 of the Company’s Certificate of Incorporation; (ii) any Common Stock, or any Common
Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after July 30, 2013; and (iii) any Common Stock issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases,
however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of
Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.27 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.28 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(b) hereof. 
 1.29 “Right of First Refusal and Co-Sale
Agreement” means that certain Amended and Restated Right of First Refusal and Co-Sale Agreement among the Company and the Investors, dated the date hereof, as amended from time to time. 

1.30 “SEC” means the Securities and Exchange Commission. 

1.31 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.32 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.33 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.34 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale
of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.35 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 

  
 - 5 - 

 1.36 “Series B Preferred Stock” means shares of the Company’s Series B
Preferred Stock, par value $0.0001 per share. 
 1.37 “Series C Directors” means those members of the Board of
Directors who are elected pursuant to Section 1(c)(i) of the Voting Agreement. 
 1.38 “Series C Preferred
Stock” means shares of the Company’s Series C Preferred Stock, par value $0.0001 per share. 
 1.39 “Series D
Directors” means those members of the Board of Directors who are elected pursuant to Section 1(c)(iii) and (iv) of the Voting Agreement. 

1.40 “Series D Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.0001 per
share. 
 1.41 “Series E Director” means any member of the Board of Directors who is elected pursuant to
Section 1(c)(v) and (vi) of the Voting Agreement. 
 1.42 “Series E Preferred Stock” means shares of the
Company’s Series E Preferred Stock, par value $0.0001 per share. 
 1.43 “Voting Agreement” means that certain Amended
and Restated Voting Agreement among the Company and the Investors, dated the date hereof, as amended from time to time. 
 2.
Registration Rights. The Company covenants and agrees as follows: 
 2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) December 31, 2018 or
(ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to the Registrable Securities then outstanding having an anticipated aggregate offering price of at least $5,000,000, then the Company shall (x) within ten (10) days
after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such
request is given by the Initiating Holders, file a Form S-l registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any
additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each
case, subject to the limitations of Section 2.1(c) and Section 2.3. 

  
 - 6 - 

 (b) Form S-3 Demand. If at any time when it is
eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1,000,000, then the Company shall
(i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date
such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other
Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and
Section 2.3. There shall be no limit to the aggregate number of registrations that the Company may be required to effect pursuant to this Section 2.1(b); provided, however, that the
Company shall not be required to effect more than one (1) registration pursuant to this Section 2.1(b) in any 12-month period. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its
stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than thirty (30) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such thirty (30) day period other than an Excluded
Registration. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective
date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two
registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the
period that is thirty (30)

  
 - 7 - 

 
days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration,
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected one registration pursuant to
Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Subsection 2.1(d) until such time as the applicable registration statement registering all of the applicable Registrable Securities has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted
as “effected” for purposes of this Subsection 2.1(d). 
 2.2 Company Registration. If the Company proposes to
register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other
than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company
shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to
terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The
expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected
by the Initiating Holders, subject only to the reasonable approval of the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this
Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all
Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be 

  
 - 8 - 

 
allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or
in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all
other securities are first entirely excluded from the underwriting. 
 (b) In connection with any offering involving an underwriting of
shares of the Company’s securities pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of
securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is
compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included
in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely
excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case
the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this
Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of
such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,”
and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Section 2.3(a), fewer than seventy percent (70%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually
included. 

  
 - 9 - 

 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC
a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to 30 days, if necessary, to keep the registration statement effective until all such Registrable Securities are
sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 - 10 - 

 (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to
this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors and their affiliated funds may implement a trading
program under Rule 10b5-l of the Exchange Act. 
 2.5 Furnish Information. It shall be a
condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all
selling Holders shall bear such expenses pro rata based upon the number of Registrable 

  
 - 11 - 

 
Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to
Section 2.1(a) or Section 2.1(b), as the case may be, in which case the Holders shall not be required to pay any of such expenses; provided, further that if, at the time of such
withdrawal, the Holders shall have learned of a change to the business of the Company that has had or would reasonably be expected to have a material adverse effect on the financial condition or business of the Company from that known to the Holders
at the time of their request and if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered with reasonable promptness after learning of such information, then the
Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be. All Selling
Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such 

  
 - 12 - 

 
registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and
each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in 

  
 - 13 - 

 
each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold
by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not
guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder
pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC
Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the
Company shall: 
 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule
144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially
reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate,
a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) 

  
 - 14 - 

 
days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such
reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling
of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so
qualifies to use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the
Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would
provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the
registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 Market Stand-off Agreement. Each Holder hereby agrees that it will not, without the prior
written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred
eighty (180) days, which period may be extended upon the request of the managing underwriter, to the extent required by any NASD or FINRA rules, for an additional period of up to 18 days if the Company issues or proposes to issue an earnings or
other public release within 18 days of the expiration of the 180-day lockup period), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to
sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11
shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and holders of more than one percent (1%) of the
Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to similar agreements. The underwriters in connection with the IPO are intended third-party beneficiaries of
this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by
the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. 

  
 - 15 - 

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing (i) the Preferred
Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar
event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the
Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail
and, if reasonably requested by the Company, shall be 

  
 - 16 - 

 
accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to
the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such
Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that
the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or
(y) in any transaction in which such Holder transfers Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Section 2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set
forth in Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with
any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or
inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; and 
 (c) as to any Holder, such time at which all shares held by such
Holder have been registered for resale under the Securities Act pursuant to an effective registration statement on Form S-l or Form S-3 filed thereunder and disposed of
in accordance with the registration statement covering them. 
 3. Financial Information and Reporting. 

3.1 Delivery of Consolidated Financial Statements. The Company shall deliver to each Investor that holds Registrable Securities: 

(a) as soon as practicable, but in any event within one hundred eighty (180) days after the end of each fiscal year of the Company
commencing with the fiscal year ending December 31, 2017, (i) a consolidated balance sheet as of the end of such year, (ii) consolidated statements of operations and of cash flows for such year, and a comparison between (x) the actual
amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as 

  
 - 17 - 

 
included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and
applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such consolidated financial statements audited and certified by independent public accountants of nationally recognized
standing selected by the Company and approved by the Board of Directors, which approval must include including the Preferred Directors (as defined in the Voting Agreement); 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited consolidated statements of operations and of cash flows for such fiscal quarter, and an unaudited consolidated balance sheet and a statement of stockholders’ equity as of the end of such fiscal
quarter, all prepared in accordance with GAAP (except that such consolidated financial statements may (i) be subject to normal year-end audit adjustments, (ii) not contain all notes thereto that may
be required in accordance with GAAP and (iii) not reflect certain equity and equity-linked instruments); 
 (c) as soon as practicable
after the end of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital
stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number
of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Investors to calculate their respective percentage equity ownership in the Company, and certified by the
chief financial officer or chief executive officer of the Company as being true, complete, and correct; 
 (d) promptly following the end of
each fiscal quarter, a current capitalization table; 
 (e) as soon as practicable, but in any event thirty (30) days before the end of
each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, statements of operations, and
statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

(f) if such Investor is a Major Investor, such other information relating to the financial condition or operations of the Company as any
Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1(f) to provide information (i) that the Company reasonably determines in good faith to be a trade secret or
confidential information; or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

  
 - 18 - 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of
the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information
set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must
do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is
no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2
Inspection. The Company shall permit each Investor, at such Investor’s expense and with reasonable advance notification, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the
Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this
Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information Rights. The covenants set forth in Section 3.1 and
Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO, or (ii) upon a Deemed Liquidation Event, whichever event occurs first. In addition, each
of such covenants set forth in Section 3.1 and Section 3.2 shall terminate as to any Investor upon the date on which all of such Investor’s shares of Preferred Stock are converted to Common
Stock pursuant to, and in accordance with, the Certificate of Incorporation (including Section 5.3 of the Certificate of Incorporation). 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor), (b) is or has been independently developed or conceived by
the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the
Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii) to any prospective purchaser of any 

  
 - 19 - 

 
Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any existing or prospective
Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain
the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required
disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor that holds any shares of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock or a number of shares of
Series B Preferred Stock equal to at least 1% of the total shares of Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) (collectively, the
“Rights Investors”), provided, in each case, that such Rights Investor is an “accredited investor” (as defined Rule 501(a) under the Securities Act). A Rights Investor shall be entitled to apportion the right of first
offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial
ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Rights Investor (“Investor Beneficial Owners”); provided that, each such Affiliate or
Investor Beneficial Owner: (x) is not a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and each of the Voting
Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Rights Investors and the other parties named therein, as an “Investor” under each
such agreement (provided that, any Competitor or FOIA Party shall not be entitled to any rights as an Investor under Subsections 3.1, 3.2 and 4.1 hereof). For the avoidance of doubt, an Investor that is not an
“accredited investor” shall not have any right to be offered or to purchase New Securities from the Company pursuant to this Section 4. 

(a) The Company shall give notice (the “Offer Notice”) to each Rights Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities; provided, however, that the Company shall provide an Offer Notice
with respect to the offer of any Clause (1) New Securities (as defined below) only to each Rights Investor that purchased Series E Preferred Stock in the First Tranche Closing (as defined in the Purchase Agreement). 

  
 - 20 - 

 (b) By notification to the Company within twenty (20) days after the Offer Notice is given,
each Rights Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities in accordance with the following: 

1. until such time as the Company has sold, after the date of this Agreement, at one or more closings, New Securities having an
aggregate purchase price of $40,000,000 or consummated the Second Tranche Closing (as defined in the Purchase Agreement), if the Company offers New Securities, Rights Investors that purchased shares of Series E Preferred Stock in the First Tranche
Closing (as defined in the Purchase Agreement) shall have the first right to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of the New Securities being offered under the Offer Notice
equal to the proportion that the number of shares of Series E Preferred Stock purchased by such Rights Investor in the First Tranche Closing bears to the total number of shares of Series E Preferred Stock issued and sold in the First Tranche
Closing; provided, however, that Rights Investors rights under this clause (1) shall only apply to the first New Securities offered after the date of this Agreement having an aggregate purchase price of $40,000,000 (the “Clause
(1) New Securities”) and any additional New Securities offered, even if offered as part of the same financing transaction as the Clause 1 New Securities, shall not be subject to this clause (1); 

2. in the event that the Company offers New Securities in a financing transaction that involves Clause (1) New Securities
and additional New Securities (the “Excess New Securities”), then Rights Investors shall have the right to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of the Excess
New Securities being offered in the financing transaction equal to the proportion that the Common Stock then held by such Rights Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise,
as applicable, of the Preferred Stock and any other Derivative Securities then held by such Rights Investor (excluding any shares of Common Stock then issuable upon conversion of the Series E Preferred Stock and any shares of Common Stock issued
upon conversion under Section 5.3 of the Certificate of Incorporation)) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative
Securities and excluding any shares of Common Stock then issuable upon conversion of the Series E Preferred Stock); and 
 3.
with respect to any New Securities offered that are not subject to the rights of Rights Investors under clause (1) or clause (2) above (the “Further Round Securities”), Rights Investors shall have the right to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such Further Round Securities equal to the proportion that the Common Stock then held by such Rights Investor (including all shares of Common Stock
then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any 

  
 - 21 - 

 
other Derivative Securities then held by such Rights Investor (excluding any shares of Common Stock issued upon conversion under Section 5.3 of the Certificate of Incorporation)) bears to
the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). 

(c) At the expiration of such twenty (20) day period, the Company shall promptly notify (i) each Rights Investor that elects to
purchase or acquire all the shares available to it under Section 4(b)(1) (a “4(b)(1) Fully Exercising Investor”) of any other Rights Investor’s failure to do likewise, (ii) each Rights Investor that elects to purchase
or acquire all the shares available to it under Section 4(b)(2) (a “4(b)(2) Fully Exercising Investor”) of any other Rights Investor’s failure to do likewise and (iii) each Rights Investor that elects to purchase or
acquire all the shares available to it under Section 4(b)(3) (a “4(b)(3) Fully Exercising Investor”) of any other Rights Investor’s failure to do likewise, as the case may be. During the ten (10) day period commencing
after the Company has given any such notice to a 4(b)(1) Fully Exercising Investor, such 4(b)(1) Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, all
or any part of the balance of any unsubscribed Clause (1) New Securities; provided, however, that in the event there are two or more such 4(b)(1) Fully Exercising Investors that choose to exercise this option for a total number of remaining
Clause (1) New Securities in excess of the number available, the remaining Clause (1) New Securities shall be allocated to such 4(b)(1) Fully Exercising Investors pro rata based on the number of shares of Series E Preferred Stock held by
such 4(b)(1) Fully Exercising Investors. During the ten (10) day period commencing after the Company has given any such notice to a 4(b)(2) Fully Exercising Investor or 4(b)(3) Fully Exercising Investor (each, a “Fully Exercising
Investor”), as the case may be, such Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the Excess New Securities or
Further Round Securities, as the case may be, for which such Fully Exercising Investor was entitled to subscribe but that were not subscribed for by the Rights Investors entitled to subscribe for such New Securities which is equal to (x) in the
case of the Excess New Securities, the proportion that the Common Stock then held by such Fully Exercising Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the
Preferred Stock and any other Derivative Securities then held by such Fully Exercising Investor (excluding any shares of Common Stock then issuable upon conversion of the Series E Preferred Stock and any shares of Common Stock issued upon conversion
under Section 5.3 of the Certificate of Incorporation)) bears to the total Common Stock of the Company (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities and excluding any shares of
Common Stock then issuable upon conversion of the Series E Preferred Stock) then held by all 4(b)(2) Fully Exercising Investors and (y) in the case of the Further Round Securities, the proportion that the Common Stock issued and held, or
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative 

  
 - 22 - 

 
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(c) shall
occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(d). 

(d) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(c),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(c), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not
less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated
within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Rights Investors in accordance with this Subsection
4.1. 
 (e) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Excluded Securities; and
(ii) shares of Common Stock issued in an IPO. 
 (f) Notwithstanding any provision hereof to the contrary, in lieu of complying with
the provisions of this Subsection 4.1, the Company may elect to give notice to the Rights Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New
Securities. Each Rights Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities calculated as set forth in Subsection 4.1(b) before giving effect to the issuance of such
New Securities. 
 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or
effect (i) immediately before the consummation of a Qualified IPO, or (ii) upon a Deemed Liquidation Event, whichever event occurs first. In addition, the covenants set forth in Section 4.1 shall terminate as to
any Investor as of the earlier of (a) the date such Rights Investor no longer holds any shares of the capital stock of the Company and (b) if applicable, the date on which all of such Rights Investor’s shares of Preferred Stock are
converted to Common Stock pursuant to, and in accordance with, the Certificate of Incorporation (including Section 5.3 of the Certificate of Incorporation). 

5. Additional Covenants. 

5.1 Insurance. The Company has and shall maintain, from financially sound and reputable insurers Directors and Officers liability
insurance, in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors determines that such
insurance should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board of Directors. 

  
 - 23 - 

 5.2 Employee Agreements. The Company will cause (i) each person now or hereafter
employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment
agreement and (ii) each Key Employee to enter into a one (1) year noncompetition, nonsolicitation and proprietary rights assignment agreement, substantially in the form approved by the Board of Directors, in the form attached hereto as
Exhibit A. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the
unanimous consent of the Preferred Directors. 
 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, all future
employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in
Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase
unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.4 Qualified Small Business Stock. The
Company shall use commercially reasonable efforts to cause the shares of Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, as well as any shares into which such shares are converted, within the meaning of
Section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement
shall not be applicable if the Board of Directors of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company or with the terms and conditions of this Agreement or
the Right of Refusal and Co-Sale Agreement or the Voting Agreement. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required
under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver
to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to
such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small
business stock” as defined in Section 1202(c) of the Code. 

  
 - 24 - 

 5.5 Board Matters. Unless otherwise determined by the vote of a majority of the directors
then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable
out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company
shall have established, or to the extent not already in place, shall cause to be established, as soon as practicable after the date hereof, and will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors. Each Board committee shall include at least one Series C Director, one Series D Director and one Series E Director. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. 
 5.7 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement), the
reasonable fees and disbursements of one counsel for the Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated
would constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including without limitation the initial and all
subsequent drafts of memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions
which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the
Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to
enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an
agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or
joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel
and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 

  
 - 25 - 

 5.8 Indemnification Matters. The Company hereby acknowledges that one (1) or more of
the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and
certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the
Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund
Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Certificate of
Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and
releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors
on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the
extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 
 5.9 Termination of
Covenants. The covenants set forth in this Section 5, except for Sections 5.6 and 5.7, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company
first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

5.10 Right to Conduct Activities. The Company hereby agrees and acknowledges that the Investors (each, together with its
Affiliates) are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The
Company hereby agrees that, to the extent permitted under applicable law, an Investor shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by any such Investor in any entity competitive with the
Company, or (ii) actions taken by any partner, officer or other representative of such Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or
otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s
confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

  
 - 26 - 

 5.11 FCPA. The Company represents that it shall not (and shall not permit any of its
subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to,
directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case,
in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and Affiliates to) cease all of its or their
respective activities, as well as remediate any actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the
FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and Affiliates to) maintain systems of internal controls (including, but
not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive
information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to
comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s
Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 1% of the Registrable Securities (subject to appropriate
adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and
address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and
conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an
Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with
those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 - 27 - 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the State of
Delaware. 
 6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes. 
 6.4 Titles and Subtitles. The titles and subtitles used in this
Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent,
if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; or (iii) one (1) business day after the business day of
deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their
addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer and the General Counsel, in the case of the Company, or to such email address,
facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street,
Boston, MA 02109, Attention: Stuart M. Falber, Facsimile: (617) 526-5000. 
 6.6 Amendments and
Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of
(i) the Company, (ii) the holders of a majority of the Registrable Securities then outstanding, (iii) Investors holding shares of Series C Preferred Stock representing at least a majority of the voting power of all shares of Series C
Preferred Stock then held by all Investors, (iv) Investors holding shares of Series D Preferred Stock representing at least sixty percent (60%) of the voting power of all shares of Series D Preferred Stock then held by all Investors, and
(v) Investors holding shares of Series E Preferred Stock representing at least sixty percent (60%) of the voting power of all shares of Series E Preferred Stock then held by all Investors; provided that the Company may in its sole
discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c)
shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.

  
 - 28 - 

 
Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of
such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all
Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). Further, this Agreement may not be amended,
and no provision hereof may be waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the
Investors hereunder, without also the written consent of the holders of at least a majority of the Registrable Securities held by the Key Holders who are then providing services to the Company. The Company shall give prompt notice of any amendment
or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be
binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Series E Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series E Preferred Stock may become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

  
 - 29 - 

 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and
agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED FN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No
delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or
nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any
other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 - 30 - 

 6.13 Acknowledgment. The Company acknowledges that certain of the Investors are in the
business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the
Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

6.14 Effectiveness. This Agreement shall become effective when executed by the Company and the holders of a majority of the Registrable
Securities then outstanding, upon which time the Prior Agreement shall be amended and restated in its entirety to read as set forth herein and this Agreement shall be binding upon each of the parties to the Prior Agreement (and any successor,
assignee or transferee of any such party), notwithstanding any failure by any such party to sign a counterpart signature page hereto. For purposes of this Section 6.14, the term “Registrable Securities” shall have the meaning given to
it in the Prior Agreement. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 31 - 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	COMPANY:
	
	APELLIS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Cedric Francois

		 	Name:  Cedric Francois
		 	Title:    Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 INVESTORS: 

Counterpart signature pages attached. 

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 New Emerging Medical Opportunities Fund III, L.P.

		 	Name of Purchaser
		
	By:	 	 /s/ Michael Sjöström

	Title:	 	CIO Sectoral Asset Mgmt
		
	Date:	 	August 7, 2017
	
	Contact Person: Maha Katabi

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Sectoral Asset Management Holding Inc.,
Hong Kong

		 	Name of Purchaser
		
	By:	 	 /s/ Michael Sjöström

	Title:	 	Director
		
	Date:	 	August 7, 2017
	
	Contact Person: Elizabeth Lazaro

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:	  	                Sofinnova Venture Partners IX, L.P.

  

			
	By:	 	 Sofinnova Management IX, L.L.C.
 its General
Partner

		
	By:	 	 /s/ James I. Healy

	Title:	 	Managing Member
		
	Date:	 	August 7, 2017
	
	Contact Person: Hooman Shahlavi

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Vivo Capital Fund VIII, L.P.

		 	Name of Purchaser
		
	By:	 	Vivo Capital VIII, LLC, its General Partner
		
	By:	 	 /s/ Albert Cha

	Title:	 	Managing Member
		
	Date:	 	August 7, 2017
	
	Contact Person: Gaurav Aggarwal

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Vivo Capital Surplus Fund VIII, L.P.

		 	 Name of Purchaser

		
	 By:
	 	 Vivo Capital VIII, LLC, its General Partner

		
	By:	 	 /s/ Albert Cha

	 Title:
	 	 Managing Member

		
	 Date:
	 	 August 7, 2017

	
	 Contact Person: Gaurav Aggarwal

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 F-PRIME CAPITAL PARTNERS HEALTHCARE

FUND V LP

		
	By:	 	 F-Prime Capital Partners Healthcare Advisors

Fund V LP, its general partner

		
	By:	 	Impresa Holdings LLC, its general partner
		
	By:	 	 Impresa Management LLC, its managing

member

		
	By:	 	 /s/ Mary Bevelock Pendergast

	Name:	 	Mary Bevelock Pendergast
	Title:	 	Vice President
		
	Date:	 	August 7, 2017
	
	Contact Person: Mary Bevelock Pendergast

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Clough Global Equity Fund

		 	Name of Purchaser
		
	By:	 	 /s/ Daniel J. Gillis

	By:	 	Daniel J. Gillis
	Title:	 	Chief Compliance Officer
		
	Date:	 	8/7/17
	
	Contact Person: Susan Moore

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Clough Global Opportunities Fund

		 	Name of Purchaser
		
	By:	 	 /s/ Daniel J. Gillis

	 By:
	 	 Daniel J. Gillis

	 Title:
	 	 Chief Compliance Officer

		
	 Date:
	 	 8/7/17

	
	 Contact Person: Susan Moore

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
 PURCHASER: 

 

			
	By:	 	 Clough Healthcare Master Fund, L.P.

		 	Name of Purchaser
		
	By:	 	 /s/ Daniel J. Gillis

	 By:
	 	 Daniel J. Gillis

	 Title:
	 	 Chief Compliance Officer

		
	 Date:
	 	 8/7/17

	
	 Contact Person: Susan Moore

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 For and on behalf of Morningside Venture Investments Ltd.

		 	Name of Purchaser
		
	By:	 	 /s/ Raymond Long Sing Tang

	Title:	 	Authorized Signatures
		
	Date:	 	August 7, 2017

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 Cormorant Private Healthcare Fund I, LP

		 	Name of Purchaser
		
	By:	 	 /s/ Bihua Chen

	Title: Managing Member of the GP
	
	Date: 8-7-17
	
	 Contact Person: Cormorant Asset Management, LLC

   Attn: Jake Abdolmohammadi

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 Cormorant Global Healthcare Master Fund, LP

		 	Name of Purchaser
		
	By:	 	 /s/ Bihua Chen

	Title:	 	Managing Member of the GP
		
	Date:	 	8-7-17
	
	 Contact Person: Cormorant Asset Management, LLC

   Attn: Jake Abdolmohammadi

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 CRMA SPV, LP

		 	Name of Purchaser
		
	By:	 	 /s/ Bihua Chen

	Title:	 	CEO of Cormorant Asset Mgmt, Its attorney-in-fact
		
	Date:	 	8-7-17
	
	 Contact Person: Cormorant Asset Management, LLC

   Attn: Jake Abdolmohammadi

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 venBio Select Fund LLC

		 	Name of Purchaser
		
	By:	 	 /s/ Scott Epstein

	Title:	 	Chief Financial Officer & CCO
		
	Date:	 	8/7/17
	
	Contact Person: Scott Epstein

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 /s/ Rob Adelman

		 	Name of Purchaser
		
	By:	 	 Rob Adelman

	Title:	 	Manager
		
	Date:	 	8/7/17
	
	Contact Person: Dave Pezeshki

 EXHIBIT A 

FINANCING SIGNATURE PAGE 

The Purchaser, as defined in that certain Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) by and among APELLIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”),
and the Purchasers (as defined in the Purchase Agreement), dated as of August 7, 2017, acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers” and
hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and conditions of (i) the Purchase Agreement as a
“Purchaser” thereunder, (ii) the Voting Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, (iii) the Investor Rights Agreement (as defined in the Purchase Agreement) as an “Investor”
thereunder and (iv) the Right of First Refusal and Co-Sale Agreement (as defined in the Purchase Agreement) as an “Investor” thereunder, and authorizes this signature page to be attached to the
Purchase Agreement, the Voting Agreement, the Investor Rights Agreement and the Right of First Refusal and Co-Sale Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date
set forth below. 
  

			
	PURCHASER:
		
	By:	 	 Epidarex Capital I, LP

		 	Name of Purchaser
		
	By:	 	 /s/ Kyparissia Sirinakis

	Title:	 	Managing Member
		
	Date:	 	August 7, 2017
	
	Contact Person: Kyp Sirinakis
	
	Email Address: kyp@epidarex.com

 SCHEDULE A 

Investors 
 New Emerging Medical
Opportunities Fund III, L.P. (Sectoral) 
 c/o Sectoral Asset Management 

1010 Sherbrooke St. West, Suite 1610 
 Montreal, QC H3A 2R7 Canada

 Sectoral Asset Management Holding Ltd. 
 c/o Sectoral Asset
Management 
 1010 Sherbrooke St. West, Suite 1610 
 Montreal,
QC H3A 2R7 Canada 
 Sofinnova Venture Partners IX, L.P. 
 3000
Sand Hill Road, Bldg. 4, Suite 250 
 Menlo Park, CA 94025 

Vivo Capital Fund VIII, L.P. 
 505 Hamilton Avenue, Suite 207

 Palo Alto, CA 94301 
 Vivo Capital Surplus Fund VIII, L.P.

 505 Hamilton Avenue, Suite 207 
 Palo Alto, CA 94301 

F-Prime Capital Partners Healthcare Fund V LP 

c/o F-Prime Capital Partners 

Attention: Mary Bevelock Pendergast 
 One Main Street, 13th Floor

 Cambridge, MA 02142 
 Fax: (617) 231-2425 
 Email: mpendergast@fprimecapital.com 

Clough Healthcare Master Fund, L.P. 
 One Post Office Square,
40th floor 
 Boston, MA 02109 
 Clough Global Equity Fund 

One Post Office Square, 40th floor 
 Boston, MA 02109 

 Clough Global Opportunities Fund 

One Post Office Square, 40th floor 
 Boston, MA 02109 

Morningside Venture Investments Limited 
 Attn: Louise Garbarino

 2nd Floor, Le Prince de Galles 
 3-5 Avenue des Citronniers 
 MC 98000, Monaco 

T: 011-377-97-97-47-37 
 F: 011-377-97-97-47-30 
 lgarbarino@thc-mgt.mc 
 Cormorant Private Healthcare Fund I, LP 

200 Clarendon Street, 52nd Floor 
 Boston, MA 021116 

Cormorant Global Healthcare 
 Master Fund, LP 

200 Clarendon Street, 52nd Floor 
 Boston, MA 021116 

CRMA SPV, LP 
 200 Clarendon Street, 52nd Floor 

Boston, MA 021116 
 Hillhouse WHP Holdings Limited 

C/o Citco B.V.I. Limited 
 Flemming House 

Wickams Cay, Road Town 
 Tortola, B.V.I. 

AJU Life Sciences Overseas Expansion Platform Fund 
 4F, 201 Teheran-ro, AJU Bldg. 
 Gangnam-gu, Seoul, Korea
135-978 
 Epidarex Capital I, LP 

7910 Woodmont Avenue, Suite 1210 
 Bethesda, MD
20814                 
 venBio Global Strategic Fund II LP 

1700 Owens Street #530 
 San Francisco, CA 94158 USA 

venBio Select Fund LLC 
 120 West 45th Street, Suite 2802 

New York, NY 10036 

 Michael Gellert 

750 Third Avenue, Suite 3300 
 New York, NY 10017 

2011 Robert de Rothschild Family Trust 
 1251 Avenue of the
Americas, 51st Floor 
 New York, NY 10020 
 Robert de
Rothschild 
 1251 Avenue of the Americas, 51st Floor 
 New
York, NY 10020 
 Robert Scherer 
 Private Client Bank, Utoquai
55 
 P.O. Box 835 

CH-8034 Zurich 

Switzerland 
 Benon Group, Ltd. 

Lenz & Staehelin, ATTN: Silvia Helbing 
 Bleicherweg 58

 Zurich 
 8027 

Switzerland 
 Edmund A. Hajim 

730 Fifth Avenue, 15th Floor 
 New York, NY 10019 

Cogut Family Partnership VII 
 c/o Pegasus 

99 River Road 
 Cos Cob, CT 06807 

Kentucky Science & Technology Corporation 
 200 West
Vine Street, Suite 420 
 Lexington, KY 40507 
 Jacques Nauer

 Loretohöhe 5 
 Zug 

6300 
 Switzerland 

 Nathalis Scherer 

c/o Robert Scherer 
 Private Client Bank, Utoquai 55 

P.O. Box 835 
 CH-8034
Zurich 
 Switzerland 
 John van Merkensteijn 

211 Central Park West, Apt. 2G 
 New York, NY 10024 

Christophe Du Bois 
 Avenue de L’Horizon N 19 

1150 Brussels 
 Belgium 

Rock Spring Ventures, LP 
 7910 Woodmont Avenue 

Suite 1210 
 Bethesda, MD 20814 

Estate of Harold Snyder 
 1965 Broadway, Apt. 21B 

New York, NY 10023 
 Annette R. Carroll and John Rowan Carroll

 1251 Winwood Drive 
 Lake Forest, IL 60045 

Lowestoft Co. 
 c/o Fiduciary Trust Co. - D+K 

175 Federal Street 
 Boston, MA 02110 

Mark Kristoff 
 35 Father Peters Lane 

New Caanan, CT 06840 
 Alan K. Docter 

101 Worth Avenue 
 Apt. 5A 

Palm Beach, FL 33480 
 Gabriel Coscas 

113 Boulevard Saint Germain 
 75006 Paris 

France 

 SAI, LLC 
 Aufman
Associates 
 2200 Georgetown Drive 
 Sewickley, PA 15143 

Brian T. Dolan 
 2770 E. Cedar Avenue 

Denver, CO 80209 
 Ross Bhappu and Candy Bhappu 

19333 E. Briarwood Place 
 Centennial, CO 80016 

Saunders Murdock & Associates 
 9960 Corporate Campus
Drive 
 Suite 3300 
 Louisville, KY 40223 

Christina Lee Brown 
 6501 Longview Lane 

Louisville, KY 40220 
 Mary Moss Greenbaum 

2233 Douglass Blvd. 
 Louisville, KY 40205 

Barry M. Fox 
 12 East 88th Street, PH 

New York, NY 10125 
 Gregory P. Murdock IRA 

34 Gould Road 
 Arlington, MA 02476 

Lewis and Bonnie Taffer 
 195 Hudson Street, 3A 

New York, NY 10013 
 Saunders Capital Group LLC 

9960 Corporate Campus Drive 
 Suite 3306 

Louisville, KY 40223 

 Herbert Wagner Revocable Trust 

Michael Lynch 
 186 Alewife Brook Pkwy. 

Cambridge, MA 02138 
 Hermitage Trust 

James Benoit 
 P.O. Box 1037 

Marion, WA 02738 
 Donald Angier T/U/W 

c/o Fiduciary Trust Co. - D+K 
 175 Federal Street 

Boston, MA 02110 
 Albert Stone 2005 Trust 

c/o Donald A. Keyser, Fiduciary Trust Company 
 175 Federal Street

 Boston, MA 02110 
 Samuel Cabot - Art. 2B Trust 

c/o Fiduciary Trust Co. - D+K 
 175 Federal Street 

Boston, MA 02110 
 Michelle Morris and Alfredo Carballude 

2902 Eminence Road 
 Hancock, NY 10023 

Donald Keyser 
 114 Larch Road 

Cambridge, MA 02138 

 SCHEDULE B 

Key Holders 
 Cedric Francois 

Potentia Pharmaceuticals, Inc. 
 6400 Westwind Way, Suite A 

Crestwood, KY 40014 
 Pascal Deschatelets 

Potentia Pharmaceuticals, Inc. 
 6400 Westwind Way, Suite A 

Crestwood, KY 40014 

 EXHIBIT A 

Form Of Noncompetition and Nonsolicitation Agreement 

 NONCOMPETITION, NONDISCLOSURE 

AND DEVELOPMENTS AGREEMENT 

This Noncompetition, Nondisclosure and Developments Agreement (“Agreement”), made as of
                    , is entered into by Apellis Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 6400 Westwind
Way, Suite A, Crestwood, KY 40014 (the “Company”), and                      (the “Employee”). 

NOW, THEREFORE, as a condition of, and in consideration of, the initial and continued employment of the Employee and of the mutual covenants
and promises contained herein, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Confidential Information. 

(a) Confidential Information. The Employee agrees that the Employee shall not, either during the Employee’s employment with
the Company, any of its subsidiaries or any parent or holding company of the Company (the Company and each such subsidiary, parent and holding company, a “Related Company” and collectively, the “Related C ompanies”) or at any
time thereafter, except as required in the performance of the Employee’s services for the Company or any other Related Company, (i) use or disclose or divulge any Confidential Information or (ii) remove or aid in the removal from the
premises of any Related Company any Confidential Information or any property or material relating thereto. 
 (b) Delivery of
Material. Upon the Company’s request at any time and for any reason, the Employee shall immediately deliver to the Company all materials (including all soft and hard copies) in the Employee’s possession which contain or relate to
Confidential Information. 
 (c) Customer Lists. The Employee acknowledges and agrees that all lists of current and prospective
customers and vendors of, and any other parties having material business relations with, the Company or any other Related Company developed before, during or after the course of the Employee’s employment with the Company or any other Related
Company are, and shall continue to be, the sole and exclusive property of such Related Company and that the Employee neither has, nor shall have, any right, title or interest therein. The Employee further acknowledges and agrees that such lists are
and must continue to be confidential, and are not readily accessible to any competitor of any Related Company. 
 (d) Former Employer
Information. During the Employee’s term of employment with the Company or any other Related Company, the Employee will not improperly use or disclose any proprietary information or trade secrets of any former or concurrent employer or other
person or entity and the Employee will not bring onto the premises of any such Related Company, any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer,
person or entity. 

 (e) Definition. For the purposes of this Agreement, “Confidential Information”
means all trade secrets and all other information of a business, financial, marketing, technical or other nature relating to the business of any Related Company including, without limitation, any customer or vendor lists, prospective customer names,
financial statements and projections, trade secrets, know-how, pricing policies, operational methods, methods of doing business, technical processes, formulae, characteristics, assays, raw data, scientific
preclinical or clinical data, records, databases, formulations, clinical protocols, designs and design projects, inventions, computer hardware, software programs, business plans and projects pertaining to any Related Company and including any
information of others that any Related Company has agreed to keep confidential; provided, that Confidential Information shall not include any information that has entered or enters the public domain through no fault of the Employee. 

2. Noncompetition and Nonsolicitation Covenants. The Employee agrees that the Employee shall not, during the period in which the
Employee is employed by any Related Company and for one year thereafter: 
 (a) directly or indirectly, individually or as a
consultant to, or employee, officer, director, stockholder, partner or other owner or participant in any business entity, other than a Related Company, engage in or assist any other person or entity to engage in any business that seeks to develop or
commercialize any diagnostic measures or treatments based on complement inhibition for, during or at the time of termination of the Employee’s employment, anywhere in the United States, the European Union, Japan and anywhere else in the world
where any Related Company does business; or 
 (b) directly or indirectly, individually or as a consultant to, or employee, officer,
director, stockholder, partner or other owner or participant in any business entity solicit, divert or take away, or attempt to solicit, divert or take away from any Related Company, or offer employment or any consultant position to, or otherwise
interfere with the business relationship of any Related Company with, (i) any person who is, or was within the one year period immediately prior to the termination of the Employee’s employment with the Company (or any other Related
Company), employed by or associated with any Related Company or (ii) any person or entity who is, or was within the one year period immediately prior to the termination of the Employee’s employment with the Company (or any other Related
Company), a customer or client of, supplier to or other party having material business relations with any Related Company. 
 3.
Inventions and Grants. 
 (a) All inventions, modifications, discoveries, designs, developments, improvements, processes, software
programs, works of authorship, grant applications, proposals, documentation, formulae, data, techniques, know-how, secrets or intellectual property rights or any interest therein (collectively, the
“Developments”) made by the Employee, either alone or in conjunction with others, at any time or at any place during the Employee’s employment with the Company (or any other Related Company), whether or not reduced to writing or
practice during such period of employment, which relate to the business in which any Related Company is engaged or in which any Related Company intends to engage, shall be the exclusive property of the Company without any further compensation to the
Employee. All Developments which are 

 
copyrightable work and relate to the business of any Related Company during such Employee’s employment with any Related Company are intended to be “work made for hire” as defined
in Section 101 of the Copyright Act of 1976, and shall be the property of the Company. The Employee shall promptly disclose such Developments to the Company. To the extent that such Developments are not the property of the Company by virtue of
this Agreement, operation of law or otherwise, the Employee shall, at the request and expense of the Company, and hereby does transfer and assign all of the Employee’s rights to such Developments to the Company and will assist the Company and
its nominees in every way, at the Company’s expense, to secure, maintain and defend the Company’s rights in such Developments. The Employee shall sign all instruments necessary for the filing and prosecution of any applications for, or
extension or renewals of, letters patent of the United States or any foreign country which the Company desires to file. The Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the
Employee’s agent and attorney-in-fact (which designation and appointment shall be deemed coupled with an interest and shall survive the Employee’s death or
incapacity), to act for and in the Employee’s behalf to execute and file any such applications, extensions or renewals (and any copyright or other applications, extensions or renewals relating to the Developments) and to do all other lawfully
permitted acts to further the prosecution and issuance of such letters patent or other such similar documents (including any copyright or other applications, extensions or renewals relating to the Developments) with the same legal force and effect
as if executed by the Employee. 
 (b) Attached hereto as Exhibit A is a list of all inventions, modifications, discoveries,
designs, developments, improvements, processes, software programs, works of authorship, documentation, formulae, data, techniques, know-how, secrets or intellectual property rights or any interest therein made
by the Employee prior to the Employee’s employment with the Company or any other Related Company (collectively referred to as “Prior Inventions”), which belong to the Employee and which relate to the business of the Company or any
other Related Company, and which are not assigned to the Company hereunder; or, if no such list is attached, the Employee represents that there are no such Prior Inventions. If in the course of the Employee’s employment with any Related
Company, the Employee incorporates into a Related Company product, process, or machine a Prior Invention owned by the Employee or in which the Employee has an interest, such Related Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, transferable, perpetual, worldwide license to make, have made, modify, use, sell and exploit such Prior Invention as part of or in connection with such product, process, or
machine to the extent the Employee is legally entitled to grant such license. 
 (c) The Employee hereby agrees to keep and maintain
adequate and current written records of all Developments made, developed, conceived or reduced to practice by such Employee (solely or jointly with others) during the term of the Employee’s employment with the Company or any Related Company.
The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 

 (d) The Employee agrees that the Employee shall not, during the period in which the
Employee is employed by a Related Company or at any time thereafter, directly or indirectly, individually or as a consultant to, or employee, officer, director, stockholder, partner, or other owner or participant in any entity, request or
cooperate with the transfer to any person or entity of any grant or other award, or of funds, projects, equipment, or activities related to or deriving from any grant or other award, which has been applied for or awarded entirely or in part to a
Related Company either as sole or joint applicant (collectively “Grant”). Should Employee cease to be employed by a Related Company before expiration or termination of any Grant on which Employee is listed as principal
investigator (“PI”) or co-PI, or should Employee resign or be removed as PI or co-PI on any Grant, Employee agrees upon the request of such Related Company to
use best efforts to assist the Related Company in transferring Employee’s responsibilities as PI or co-PI to another employee of the Related Company acceptable to the agency or other entity that awarded
the Grant or in identifying and recruiting an individual acceptable to the agency or other entity that awarded the Grant to replace Employee as PI or co-PI. The Related Company shall pay Employee’s
reasonable expenses associated with provision of such assistance. 
 4. Injunctive and Other Equitable Relief, etc. The Employee
acknowledges that the services to be rendered by the Employee under the terms of this Agreement are of a special, unique and extraordinary character, which gives them a peculiar value, the loss of which cannot be reasonably or adequately compensated
in damages in any action at law. The Employee further acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company or any Related Company and are reasonable for such
purpose and that breach of his or her obligations under Sections 2 or 3 of this Agreement will cause irreparable harm. By this reason, the Employee consents and agrees that if the Employee violates any of the provisions of this Agreement, the
Company or any other Related Company shall be entitled, in addition to any other remedies it may have at law, to the remedies of injunction, specific performance and other equitable relief for such a violation by the Employee. This Section 4
shall not, however, be construed as a waiver of any of the rights which the Company or any other Related Company may have for damages or otherwise. 

5. Other Agreements. The Employee represents and warrants that the Employee’s performance of all the terms of this Agreement and as
an employee of any Related Company does not and will not breach any other employment, consulting, noncompetition, nondisclosure, confidentiality or other agreement to which the Employee is a party or by which the Employee is bound. 

6. Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal
delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other
in accordance with this Section 6. 
 7. Not a Contract of Employment; Notification of New Employer. The Employee understands
that this Agreement does not constitute a contract of employment or give the Employee any rights to employment or continued employment with any Related Company. In the event that the Employee is no longer an employee of the Company, the Employee
consents to notification by the Company to the Employee’s new employer or its agents regarding the Employee’s rights and obligations under this Agreement. 

 8. Governing Law; Severability. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the State of Kentucky. This Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision hereof shall be prohibited or invalid under any such law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating or nullifying the remainder of such provision or any other provisions of this Agreement. If any one or more of the provisions contained in this
Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provisions shall be construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by
applicable law. The Employee hereby consents to (a) service of process, and to be sued, in the State of Kentucky and (b) to the jurisdiction of the federal and state courts located within the State of Kentucky, as well as to the
jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of any of the Employee’s obligations hereunder, and the Employee expressly waives any and all
objections he or she may have as to venue in any such courts. 
 9. Photographs. The Employee hereby acknowledges and agrees that any
Related Company which employs or employed the Employee may use photographs of the Employee (whether or not the Employee is identified by name) during and after the Employee’s employment with such Related Company in connection with the
reasonable business purposes of such Related Company. 
 10. Miscellaneous. The terms and conditions of this Agreement shall apply to
the Employee’s employment with the Company and/or any other Related Company, and each subsidiary, parent or holding company of the Company shall be an intended third party beneficiary of this Agreement. As used in this Agreement, the terms
“employment,” “employ” or words of similar import shall include any period in which the Employee is a consultant to any Related Company. No delay or omission by the Company (or any other Related Company) in exercising any right
under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by any Related Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on
any other occasion. No waiver of this Agreement or any provision hereof shall be binding upon the party against whom enforcement of such waiver is sought unless it is made in writing and signed by or on behalf of such party. This Agreement may be
amended or modified only by a written instrument executed by both the Company and the Employee. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any
section of this Agreement. This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective heirs, executors and administrators, successors and permitted assigns, except that the obligations of the Employee
hereunder are personal and may not be assigned without the Company’s prior written consent. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral,
relating to the subject matter of this Agreement. This Agreement may be executed in any number of counterparts, including counterparts by facsimile, each of which shall be deemed an original, but all of which when taken together shall constitute one
and the same Agreement. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set
forth above. 
  

	
	APELLIS PHARMACEUTICALS, INC.
	
	By                                      
                                         
                  
	Pascal Deschatelets, PhD, COO
	
	By                                      
                                         
                  

 [Signature Page to Noncompetition, Nondisclosure, and Developments Agreement] 

 EXHIBIT A 
  

					
	Prior Invention	  	Date	  	Identification Number or Brief Description

 NONEEX-4.3

 Exhibit 4.3 

Exhibit E 
 VOTING
AGREEMENT 
 This is a Voting Agreement (this “Agreement”), dated as of September 8, 2015 between Apellis
Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Potentia Pharmaceuticals, Inc., a Delaware corporation (“Potentia”). 

A. This Agreement is being executed and delivered under the terms of the Asset Purchase Agreement dated as of September 24, 2014 between
Apellis and Potentia (the “Asset Purchase Agreement”) pursuant to which Apellis or its Nominee will purchase substantially all of the assets and assume certain of the liabilities of Potentia, for which Apellis will pay consideration
consisting of 8,200,000 shares of Apellis common stock (such number of shares being subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting Apellis common stock occurring after
the date of the Asset Purchase Agreement and prior to the Closing) (such shares and any other securities of the Company, by whatever name called, which carry voting rights, which are subsequently acquired by Potentia being referred to collectively
as the “Transaction Shares”). 
 C. The Asset Purchase Agreement provides that Potentia shall execute and deliver this
Agreement to Apellis at the Closing of the Transaction. 
 D. For purposes of this Agreement, capitalized terms used and not defined herein
shall have the respective meanings ascribed to them in the Asset Purchase Agreement. 
 NOW, THEREFORE, in consideration of the premises and
for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

1. Representations. 
 Potentia represents
and warrants to Apellis that Potentia has full corporate power and authority to enter into, execute and deliver this Agreement and to perform fully Potentia’s obligations hereunder (including the proxy described in Section 2(b) below).
This Agreement has been duly and validly executed and delivered by Potentia and constitutes the legal, valid and binding obligation of Potentia, enforceable against Potentia in accordance with its terms. 

2. Agreement to Vote Shares; Irrevocable Proxy. 

(a) Potentia agrees that during the term of this Agreement: 

 (i) on any matter submitted for a vote of holders of common stock of Apellis, Potentia will vote
(or abstain from voting) the Transaction Shares in the same ratio(s) as the other holders of Apellis common stock vote their shares. For example, if the other holders of Apellis common stock vote 87% in favor of a resolution, 9% against, and 4%
abstain, then the Transaction Shares will be voted in the same ratios; 
 (ii) if holders of common stock of Apellis are requested to vote
their shares through the execution of an action by written consent in lieu of any meeting of stockholders of Apellis, Potentia will execute a written consent or consents, only with respect to that percentage of the Transaction Shares equal to the
percentage of the shares of Apellis common stock held by the other holders of Apellis common stock for which written consents are executed and delivered. 

(b) Potentia hereby constitutes and appoints Apellis and any designee of Apellis, and each of them individually, as its proxies and
attorneys-in-fact, with full power of substitution and resubstitution, to represent and vote (or act by written consent) during the term of this Agreement with respect to the Transaction Shares in the manner set forth in Section 2(a). This
proxy and power of attorney is given in consideration of the agreements and covenants of Apellis and Potentia in connection with the transactions contemplated by this Agreement and the Asset Purchase Agreement and, as such, is coupled with an
interest and shall be irrevocable unless and until this Agreement terminates. Potentia shall take such further action or execute such other instruments as may be necessary to effectuate the intent of this proxy. The proxy and power of attorney
granted hereunder shall terminate upon the termination of this Agreement. 
 3. No Voting Trusts or Other Arrangement. 

Except as provided in the Voting Agreement dated as of July 30, 2013 by and among Apellis and the Stockholders (as defined therein), as
amended from time to time (the “Existing Voting Agreement”) to which Potentia shall become a party on the date hereof, Potentia revokes any and all previous proxies with respect to the Transaction Shares and agrees that it will not,
and will not permit any entity under Potentia’s control to, deposit any of the Transaction Shares in a voting trust, grant any proxies with respect to the Transaction Shares or subject any of the Transaction Shares to any arrangement with
respect to the voting of the Transaction Shares other than agreements entered into with Apellis. 
 4. Transfer and Encumbrance; Legend. 

(a) Potentia agrees that during the term of this Agreement, Potentia will not, directly or indirectly, transfer, sell, offer, exchange, assign,
or otherwise dispose of (“Transfer”) any of the Transaction Shares or enter into any contract, option or other agreement with respect to, or consent to, a Transfer of any of the Transaction Shares or Potentia’s voting interest
therein, except as permitted by the Asset Purchase Agreement. 

  
 2 

 Any attempted Transfer of the Transaction Shares or any interest therein in violation of this Section 4
shall be null and void. This Section 4 shall not prohibit a Transfer of the Transaction Shares to a successor to Potentia in connection with the reorganization of Potentia as a Delaware limited liability company as contemplated by the Asset
Purchase Agreement; provided that the successor agrees in a writing reasonably satisfactory in form and substance to Apellis to be bound by all of the terms of this Agreement. 

(b) All certificates representing Transaction Shares owned or hereafter acquired by Potentia or any transferee of Potentia bound by this
Agreement shall have affixed thereto a legend substantially in the following form: 
 “The shares of stock represented by this
certificate are subject to certain voting agreements as set forth in a Voting Agreement, as amended and/or restated from time to time, by and among the registered owner of this certificate and the Company, a copy of which is available for inspection
at the offices of the Secretary of the Company.” 
 5. Termination. 

This Agreement shall terminate upon the earliest to occur of (a) the date Potentia or any successor to whom Potentia has transferred the
Transaction Shares as permitted by this Agreement and who is bound by the terms of this Agreement ceases to own or control any Transaction Shares, (b) the Sale of the Buyer, or (c) an Initial Public Offering, as those terms are defined in
the Asset Purchase Agreement. 
 6. Specific Performance. 

Each Party acknowledges that it will be impossible to measure in money the damage to the other Party if a Party fails to comply with any of the
obligations imposed by this Agreement, that every such obligation is material and that, in the event of any such failure, the other party will not have an adequate remedy at law or damages. Accordingly, each Party agrees that, in addition to
remedies at law or damages, the other Party shall be entitled to an injunction to prevent breaches of this Agreement and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United
States or any state thereof having jurisdiction over the Parties and the matter, and will not oppose such relief on the basis that the other Party has an adequate remedy at law. Each Party agrees that it will not seek, and agrees to waive any
requirement for, the securing or posting of a bond in connection with the other party’s seeking or obtaining such equitable relief. 
 7. Entire
Agreement. 

	

  
 3 

 This Agreement, together with the Existing Voting Agreement, supersedes all prior agreements,
written or oral, between the Parties with respect to the subject matter hereof and contains the entire agreement between the parties with respect to the subject matter hereof. This Agreement may not be amended or supplemented, and no provisions
hereof may be modified or waived, except by an instrument in writing signed by both of the parties hereto. No waiver of any provisions hereof by either party shall be deemed a waiver of any other provisions hereof by such party, nor shall any such
waiver be deemed a continuing waiver of any provision hereof by such party. To the extent the the provisions of the Existing Voting Agreement conflict with the provisions of this Agreement, the provisions of the Existing Voting Agreement shall
control and supersede the provisions of this Agreement. 
 8. Notices. 

All notices, requests, demands, claims, and other communications hereunder shall be in writing. Any notice, request, demand, claim, or other
communication hereunder shall be deemed duly delivered four business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next business day delivery via a
reputable nationwide overnight courier service, in each case to the intended recipient as set forth below: 
  

			
	If to the Seller:	  	Copy to:
		
	 Potentia Pharmaceuticals, Inc.
 6400 Westwind
Way, Suite A
 Crestwood, KY 40014
 Attn: David M. Darst,
Director
	  	 Frost Brown Todd LLC
 400 W. Market Street,
Suite 3200
 Louisville, KY 40202
 Attn: Alan K.
MacDonald

		
	If to the Buyer:	  	Copy to:
		
	 Apellis Pharmaceuticals, Inc.
 6400 Westwind
Way, Suite A
 Crestwood, KY 40014
 Attn: Cedric Francois,
CEO
	  	 WilmerHale
 60 State Street

Boston, MA 02109
 Attn: Stuart Falber.

 Either Party may give any notice, request, demand, claim, or other communication hereunder using any other
means (including personal delivery, expedited courier, messenger service, telecopy, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it
actually is received by the party for whom it is intended. Either Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other Party notice in the manner herein
set forth. 
 9. Miscellaneous. 

  
 4 

 (a) This Agreement shall be governed by and construed in accordance with the internal laws of the
State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than those of the State of
Delaware. 
 (b) Each Party (a) submits to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New
Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement, (b) agrees that all claims in respect of such action or
proceeding may be heard and determined in any such court, (c) waives any claim of inconvenient forum or other challenge to venue in such court, (d) agrees not to bring any action or proceeding arising out of or relating to this Agreement
in any other court and (e) waives any right it may have to a trial by jury with respect to any action or proceeding arising out of or relating to this Agreement. Each Party agrees to accept service of any summons, complaint or other initial
pleading made in the manner provided for the giving of notices in Section 8, provided that nothing in this Section 9 shall affect the right of either Party to serve such summons, complaint or other initial pleading in any other manner
permitted by law. 
 (c) If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such
invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other
provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the
transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 
 (d) This Agreement may be
executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. 

(e) Each Party shall execute and deliver such additional documents as may be necessary or desirable to effect the transactions contemplated by
this Agreement. 
 (f) All Section headings herein are for convenience of reference only and are not part of this Agreement, and no
construction or reference shall be derived therefrom. 
 (g) Neither Party may assign any of its rights or obligations under this Agreement
without the prior written consent of the other Party, except that Potentia may assign, in its sole discretion, all or any of its rights, interests and obligations hereunder to 

  
 5 

 
a successor as provided in Section 4. Any assignment contrary to the provisions of this Section 9(g) shall be null and void. 

[SIGNATURE PAGE FOLLOWS] 

  
 6 

 IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date first written above.

  

			
	APELLIS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Cedric Francois

	Name:	 	Cedric Francois
	Title:	 	Chief Executive Officer
	
	POTENTIA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Cedric Francois

	Name:	 	Cedric Francois
	Title:	 	Chief Executive Officer

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]